Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 10 results.
User Information
Export Records
  1. 1.   Targeting the extrinsic apoptosis signaling pathway for cancer therapy
  2. Sayers, T. J.
  3. Cancer Immunology Immunotherapy. 2011, Aug; 60(8): 1173-1180.
  1. 2.   Differential control of the CCAAT/enhancer-binding protein beta (C/EBP beta) products liver-enriched transcriptional activating protein (LAP) and liver- enriched transcriptional inhibitory protein (LIP) and the regulation of gene expression during th
  2. Li, Y.; Bevilacqua, E.; Chiribau, C. B.; Majumder, M.; Wang, C. P.; Croniger, C. M.; Snider, M. D.; Johnson, P. F.; Hatzoglou, M.
  3. Journal of Biological Chemistry. 2008 283(33): 22443-22456.
  1. 3.   Sensitizing tumor cells to immune-mediated cytotoxicity
  2. Shanker, A.; Sayers, T.
  3. Immune-Mediated Diseases: From Theory to Therapy. 2007; 601 : 163-171.
  1. 4.   Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors
  2. Khan, T.; Stauffer, J. K.; Williams, R.; Hixon, J. A.; Salcedo, R.; Lincoln, E.; Back, T. C.; Powell, D.; Lockett, S.; Arnold, A. C.; Sayers, T. J.; Wigginton, J. M.
  3. Journal of Immunology. 2006, MAY 15; 176(10): 6302-6312.
  1. 5.   Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy
  2. Sayers, T. J.; Murphy, W. J.
  3. Cancer Immunology Immunotherapy. 2006, JAN; 55(1): 76-84.
  1. 6.   Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity
  2. Sun, K.; Wilkins, D. E. C.; Anver, M. R.; Sayers, T. J.; Panoskaltsis-Mortari, A.; Blazar, B. R.; Weiniak, L. A.; Murphy, W. J.
  3. Blood. 2005, NOV 1; 106(9): 3293-3299.
  1. 7.   Proteasome inhibition upregulates the cell surface expression of receptors for IFN-gamma and TNF-alpha on murine neuroblastoma cells and enhances the proapoptotic and overall antitumor activity of systemic cytokine therapy in murine neuroblastoma tumors
  2. Khan, T.; Stauffer, J. K.; Williams, R.; Hixon, J. A.; Salcedo, R.; Lincoln, E.; Back, T. C.; Lockett, S.; Sayers, T. J.; Wigginton, J. M.
  3. Journal of Immunotherapy. 2005, NOV-DEC; 28(6): 640-640.
  1. 8.   Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib
  2. Sun, K.; Welniak, L. A.; Panoskaltsis-Mortari, A.; O'Shaughnessy, M. J.; Liu, H. Y.; Barao, I.; Riordan, W.; Sitcheran, R.; Wysocki, C.; Serody, J. S.; Blazar, B. R.; Sayers, T. J.; Murphy, W. J.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2004 101(21): 8120-8125.
  1. 9.   Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors
  2. Khan, T.; Hixon, J.; Stauffer, J.; Lincoln, E.; Back, T.; Sayers, T.; Wigginton, J.
  3. Journal of Immunotherapy. 2004, NOV-DEC; 27(6): S57-S57.
  1. 10.   RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer
  2. Fang, S.; Lorick, K. L.; Jensen, J. P.; Weissman, A. M.
  3. Seminars in Cancer Biology. 2003 13(1): 5-14.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel